ArticlePaediatrics & child health2026
Newborn screening for hemoglobinopathies: a review of Canadian data from 2020 to 2023.
Article in Paediatrics & child health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Newborn screening (NBS) for hemoglobinopathies continues to grow in Canada. This study aims to describe the current diagnostic rates of hemoglobinopathies and hemoglobinopathy carriers through NBS programs in Canada, which has never been reviewed comprehensively across the country. Methods: We requested collaboration from provincial or territorial NBS programs in Canada on this cross-sectional study which included screening data from January 1, 2020 to December 31, 2023, inclusive. The data collection encompassed screening for hemoglobinopathies (including sickle cell disease, thalassemia, and other variants), hemoglobinopathy carriers, and relevant laboratory information. Results: 90% of Canadian newborns were screened for hemoglobinopathies by NBS between the study dates. On average, 1 in 2000 newborns is diagnosed with a hemoglobinopathy by NBS across Canada. Sickle cell disease (SCD) (including HbS/S, HbS/C, HbS/β Conclusion: This study established hemoglobinopathy and carrier identification rates among children born in Canada essential in establishing the epidemiology of SCD, Thalassemia, and other hemoglobinopathies. When compared with previous publications, the findings of this study suggest an increase in the incidence of SCD in Canadian newborns over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.